Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Fluorine-19 MRI for detection and quantification of immune cell therapy for cancer

Fig. 1

Immune cells labeled with PFC and in vivo distribution. a Murine DCs labeled with dual-mode BODIPY-19F PFC nanoemulsion as seen in fluorescent micrographs of the cytoplasm (red), along with Hoechst labeled nuclei (blue) and the CD45-FITC labeled cell surface (green). b Murine primary activated T cells labeled with dual-mode PFC nanoemulsion showing cytoplasmic localization of CD4-FITC labeled cell surface (green, upper left), the PFC nanoemulsion (red, upper right), white-light image of labeled T cells (lower left) and fusion image of CD4-FITC-PFC (lower right). Scale bar is 20 μm. c NK cells isolated from a Balb/c spleen and incubated with a dual-mode PFC agent (BODIPY-19F) for 24 h, then incubated with CFSE for 15 min. Upper left: Darkfield microscopy of a Balb/c NK cell. Upper right: BODIPY-19F (orange) is seen in the entire cell. Lower left: CFSE (green) is taken up in the cell membrane. Lower right: Fusion image showing labeling with BODIPY-19F and CFSE. Scale bar is 10 mm. d Biodistribution quantification of fixed tissue samples by 19F NMR 2 or 7 days after human CAR T cell treatment in subcutaneous glioma (U87-EGFRvIII) bearing SCID mice. e 1H/19F overlay MRI showing PFPE-labeled antigen specific T cells in the draining lymph node of a BALB/c mouse locally injected with chicken ova. R indicates a reference capillary used for quantification. (Figure adapted from References [22, 35, 40])

Back to article page